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1. Introduction to Skeletal Tissues 
The fossil records and phylogenetic systematics indicate that mineralized tissues have 
existed in a myriad of chemical forms and in numerous configurations for millions of 
years. Close examination of fossilized long bones and vertebrae indicates that both 
osseous and cartilage-like tissues appeared early in evolution, indeed, it was thought 
that cartilage, a poorly organized tissue, may have predated bone. However, closer 
examination indicates that while a cartilaginous skeleton is an optimal structure for 
organisms living in aqueous environments, it was likely preceded by the denser and 
mechanically stronger mineralized bone. Romer noted in his paper to the NY Academy 
of Sciences that: 
“the early vertebrates had a considerable degree of ossification which was followed in a 
majority of cases by a slump toward a cartilaginous condition. Bone is an ancient, 
rather than a relatively new, skeletal material in the history of vertebrates” 1 
We are just now beginning to understand the complex interplay between all of these 
mineralized tissues and other tissues in the body. For example, Karsenty’s laboratory 
has shown that regulation of bone mass is coordinated with both energy metabolism 
and even fertility. 2 
Not surprisingly, bone mass,  structure and function is tightly regulated. In the adult, this 
is achieved by two active and coupled processes, bone resorption and bone formation. 
Prime regulators of these processes include hormones, especially estrogen, parathyroid 
hormone (PTH) and parathyroid hormone-related protein (PTHrP) and vitamin D 
metabolites. Bone marrow-derived osteoblasts are responsible for new bone formation  
while macrophage-like osteoclasts mediate the resorptive process. The activities of 
these cell types are linked through a bone remodeling cycle (Fig 1).  Osteoclasts 
activate the cycle by inducing the resorption of old bone; this activity is followed by a 
formative phase during which osteoblasts synthesize new bone to replace the resorbed 
tissue. Those osteoblasts that become engulfed in the mineralized bone, osteocytes, 
play a pivotal role in functionally adapting the tissue to applied mechanical forces As will 
be highlighted in this review, autophagy is relevant for the  survival and function of each 
of these cell types within their highly specialized matrices.  
When the equilibrium between these two processes is disturbed, and there is excessive 
bone formation this can lead to over mineralization of bone or osteopetrosis. More 
frequently, there is increased bone loss leading to a porotic state i.e. osteopenia or 
osteoporosis.  Osteoporosis, or more commonly post-menopausal osteoporosis, is a 
condition which increases bone fracture risk thereby challenging the quality of life and 
longevity of elderly women and men.3. The relationship between the autophagic 
pathway and osteoporosis, was highlighted in a Genome-wide Association Study 
(GWAS) of wrist bone mineral density; the pathway-based analysis showed significant 
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associations with regulation-of-autophagy genes including ATG (autophagy related 
gene)12, PIK3C3, , PRKAA2, ATG5 GABARAPL1, BECN1, IFNA13 and ATG74. The 
authors related variants in these genes to the pathogenesis of osteoporosis in terms of 
modulating factors required for bone formation and/or remodeling.   
While a great deal of new information is accruing concerning skeletal cell homeostasis, 
there is growing awareness that autophagy enables osteoblasts, osteoclasts and 
chondrocytes to survive within a hypoxic, and even hypertonic environment. In this way, 
cells can overcome stressor challenges and nutrient deficiencies and, for osteocytes 
and articular chondrocytes fulfill their fates as exceedingly long-lived terminally 
differentiated cells. The focus of this review is to examine the significance of the 
autophagic process in terms of the functional demands of the skeleton in growth and 
homeostasis, and to provide evidence that disregulation of autophagy is involved in the 
pathogenesis of diseases of bone (Paget’s disease of bone, PDB) and cartilage 
(osteoarthritis, OA, and the mucopolysaccharidoses, MPS).  (see Table 1) 
 
2. Osteoblast and Osteocyte Function and Autophagy 
Signaling Pathways Regulating Osteoblast Activity and Autophagy: Osteoblasts 
secrete the organic matrix of bone (osteoid) and participate in its mineralization. During 
its encasement in bone, the osteoblast becomes fully differentiated and assumes the 
morphology and function of an osteocyte (see later and Fig. 1). It is likely that the 
physiological stimulus for new bone formation is linked to intermittent shifts in PTH 
levels and the resorptive activities of osteoclasts which release growth factors such 
transforming growth factor-β (TGF-β), insulin-like growth factors and bone 
morphogenetic proteins (BMPs), from the extracellular matrix of the bone. In addition, a 
neuronal involvement cannot be excluded since bone mass is responsive to the 
sympathetic tone of the nervous system, through modulation of the β2-adrenergic 
receptor/cAMP signaling system.5 During resorption, release of these buried agents 
from the resorbing tissue promotes osteoblast migration, activation and even new bone 
formation.  
The BMPs are clinically powerful bone forming agents that bind to a common cognate 
receptor on osteoblasts, and transduce signals through the Smad signaling system. The 
functional activity of the BMP ligands are regulated by extracellular protein antagonists 
that include noggin, chordin and sclerostin.6 That BMPs may regulate autophagy is 
suggested by the studies of Cao et al.7 who showed that noggin reduced LC 
(microtubule-associated protein 1 light chain)3-II levels, albeit in acute pancreatitis cells; 
this was overcome by administration of BMP-2 which  increased the levels of both 
BECLIN I and LAMP2. Indeed, a mutation in the BMP type I activin receptor-like kinase 
2 causes a rare and very disabling disease, Fibrodysplasia Ossificans Progressiva. 
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Whether disease progression is related to expression of an autophagic phenotype 
awaits further study. 
Activities of proteins of the Wnt/β-catenin pathway are major regulators of chondrocyte 
and osteoblast function. Wnt signaling plays a major role in regulating stem cell 
commitment to the osteoblast lineage and osteoblast differentiation. In tumor and 
hepatic cells, Wnt signaling has been negatively linked to autophagy. This is mediated 
through the interaction of Dishevelled (Dvl2) which binds to the autophagy receptor 
sequestosome 1 (SQSTM1)/p62 (see later) which in turn facilitates LC3-mediated 
autophagosome recruitment, ubiquitylation and degradation.8 Likewise, activation of the 
Wnt/β-catenin pathway is central to the pathogenesis of both rheumatoid arthritis and 
OA. While it is tempting to speculate that activation of this pathway suppresses 
autophagy and enhances osteoblast or chondrocyte death, this relationship has not as 
yet been fully established.  
The functional role of autophagy in the osteoblast is still largely unexplored, particularly 
in vivo. However, several autophagy-related proteins profoundly impact osteoblast 
biology. The autophagy receptor Neighbor of Breast Cancer Susceptibility 1 gene 
(NBR1) is involved with targeting ubiquitinated cargos to the autophagosome. 9 It fulfills 
this function by interacting with ATG8 (LC3) protein family members through its LC3-
interacting region (LIR) and with target proteins through the ubiquitin-associated (UBA) 
domain. A knock-in mouse model with deletion of both LIR and UBA domains in the 
NBR1 locus results in increased osteoblast differentiation and activity. 10 This aberrant 
osteoblastic activity appears to be dependent on p38 MAPK hyperactivation. The 
moderate increase in the autophagy receptor SQSTM1 in osteoblasts isolated from 
NBR1 knock-in mice can impair proteasomal function and activate the stress responsive 
transcription factor NF-E2 related factor (NRF2), which results in the induction of many 
cytoprotective genes. 
At least two families of transcription factors with known roles in autophagy control 
osteoblast survival and function. Of these, family of forkhead transcription factors 
(FOXO) serves key roles in cell growth, cell proliferation, DNA repair, cell cycle arrest, 
reactive oxygen species (ROS) generation, energy homeostasis and glucose 
metabolism.11 FOXO1, 3, 4 and 6 are downstream of early signaling events in the 
insulin pathway and negatively regulate serine/threonine protein kinase (AKT) 
signaling.12  FOXO activation potently induces autophagy by directly binding to the 
promoter regions of target genes.  Genetic deletion of FOXOs in osteoblasts induces 
oxidative stress and increased apoptosis mimicking the aging process. Conversely, 
FOXO3 overexpression prevents bone loss associated with aging.13 Since autophagy 
has an important cytoprotective role against oxidative stress and other aging related 
phenotypes, and with glucosamine promotes autophagic flux in chondrocytes, 14  it is 
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tempting to consider that the role of FOXO in maintaining bone homeostasis is at least, 
in part, mediated by the induction of autophagy. 
Activating transcription factor 4 (ATF4), a member of the CREB family of B ZIP proteins, 
is required to maintain osteoblast function and promote terminal differentiation; it also 
protects cells from amino acid starvation and enhances amino acid import into cells.  
Changes in ATF4 activity have been linked to skeletal manifestations of two human 
genetic diseases, Coffin-Lowry syndrome and neurofibromatosis type I. It was shown 
that this transcription factor induces osteoblast-specific gene expression in fibroblasts 
together with osteocalcin synthesis, thus predisposing these cells to aberrant mineral 
deposition.15 Interestingly ATF4 is thought to promote cell survival through the 
transcription of several autophagy genes including MAP1LC3B and ATG5. Elefteriou et 
al. 16 noted that   the increased bone-mass phenotype resulting from neurofibromin 
(NF1) deficiency can be rescued through nutritional restriction of protein intake, a 
finding that would strongly suggest that a link exists between expression of this protein 
and autophagic flux.   
Autophagy and the Osteoblast–Osteocyte Transition: In contrast to the short half 
lives (days/weeks) of osteoblasts, osteocytes are very long-lived cells that exhibit an 
architecture closer to neurons than cartilage or bone cells. The basic features of the 
osteocyte is a cell subsumed into mineralized bone lacunae with a large number of long 
dendritic processes contained in bone canals (canaliculi) many of which interconnect 
with other osteocytes to form a syncytium as well as interacting with osteoblasts and 
bone lining cells (Fig. 1). It is likely that their primary role is mechanotransduction i.e. 
converting mechanical forces on the bone into biological signals that serve to promote 
the remodeling process. While supporting little biological activity, there is evidence that 
like osteoblasts, these cells can express the cytokine Receptor activator of nuclear 
factor kappa B ligand (RANKL) (see later) and thereby influence osteoclastogenesis 
and resorption. Osteocytes can also secrete sclerostin which inhibits signaling and 
possibly enhances osteocyte apoptosis through the Wnt signallng pathway. Not 
surprisingly, studies by Zahm et al.17 clearly showed that in situ a considerable number 
of osteonal osteocytes display a punctuate distribution of LC3-II protein indicative of a 
basal level of autophagy (Fig. 1).  
In addition in culture, using pre-osteocyte-like murine (MLO-A5) cells, autophagy was 
found to be upregulated following nutrient deprivation and hypoxic culture, stress 
conditions that osteocytes encounter in vivo (see Fig.1, Table 1).  Furthermore, in 
response to calcium stress, the transcription factor hypoxia inducible factor (HIF)-1 
regulated MLO-A5 autophagy, indicating that low pO2 may serve as a positive regulator 
of autophagy in this cell type. Lastly, it should be mentioned that low-dose 
glucocorticoid therapy profoundly influences osteocyte function and increases 
autophagic activity and anti-oxidative responsiveness 30-fold. High doses reduce both 
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the expression of genes encoding anti-oxidant proteins and the number of autophagic 
osteocytes.18 Bone formation, measured by serum osteocalcin and surface-based 
histomorphometry, was greatly reduced by chronic or high dose glucocorticoid 
treatment. Xia et al. 19 proposed that modification of the oxidative and autophagic 
pathways may provide promising new targets for maintaining bone formation in the 
presence of glucocorticoids while preserving bone mass.  
 
3. Osteoclastogenesis, Osteoclast Function and Autophagy  
Regulation of Osteoclastogenesis: At remodeling sites, hematopoietic mononuclear 
myeloid stem cells, mostly resident in the bone marrow, commit to the osteoclast 
phenotype and migrate to the tissue surface. When activated, the terminally 
differentiated osteoclast becomes tightly adherent to the bone surface.  Attachment is 
mediated through one or more specialized structures termed podosomes. The 
podosome contains bands of actin filaments, as well as F-actin and actin monomers. At 
the bone surface, circumferentially bounded by the podosome, secretory lysosomes 
fuse with specialized domains of the plasma membrane to form a ruffled border.  This 
undulating membrane is the site for secretion and externalization of proteases and 
hydrochloric acid; the acid dissolves the mineral phase of bone, while key proteases 
such as matrix metalloproteinase (MMP)9 and13 and cathepsin K, hydrolyse the 
collagen-rich organic bone matrix.20  
Differentiation of the adherent cells into an active osteoclast is dependent on 
macrophage colony-stimulating factor (M-CSF) and RANKL. 21 Following fusion with 
other mononuclear precursors of the macrophage–monocyte lineage, they form 
multinucleated giant cells. 22 Recruitment is chemokine-dependent, especially 
chemokine (C-X-C motif) ligand (CXCL) 12 which regulates cell migration. Recently, a 
lysophospholipid-derived from sphingomyelin, sphingosine 1-phosphate (S1P), has 
been shown to be an osteoclast chemoattractant. 23  Osteoclasts express the S1P 
receptor, and by modulating the activity of mechanistic target of rapamycin (MTOR), 
S1P counteracts autophagy and promotes apoptosis. 24 Lee et al. 25have shown that 
S1P levels were higher in postmenopausal women and possibly due to increased bone 
resorption, its action is associated with low bone mineral density.  
While differentiating osteoclasts populate the surface and interior of bone trabeculae, 
the local environment is probably hypoxic. Arnett et al. 26 showed that a low pO2 
promoted increased expression of BCL2/adenovirus E1B 19kDa interacting protein 
(BNIP)3. BNIP3, increased autophagic flux and LC3 recruitment to autophagosomes 
and osteoclast differentiation. These observations fueled the speculation that a HIF-1α--
BNIP3 signaling pathway promoted osteoclastogenesis and differentiation. DeSelm and 
colleagues showed that ATG5, ATG7 and ATG4B and LC3 are required for 
osteoclastogenesis and activation of bone resorption. 28 ATG5 and ATG7 promoted 
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bone resorptive activities in vivo and in vitro and serve to target lysosomes to the actin 
ring of the functioning osteoclast. However, neither protein influenced 
osteoclastogenesis, the numbers of nuclei in the osteoclasts, the presence of secretory 
lysosomes or even the expression of actin ring proteins. ATG4B modulation of LC3, 
blocked both resorptive activity and expression of cathepsin K. These findings lend 
support to the notion that lysosomal targeting is regulated by Atg5, Atg7, LC3, and 
Atg4B, while control of bone resorption is independent of autophagic activity. 28 This 
concept was further developed by Chung et al who knocked down LC3 and confirmed 
that it did not influence multinucleation, although it inhibited actin ring formation, and 
cathepsin K release. 29 Using the ATG5 knockdown, these workers showed that the 
lowered amount of LC3-II protein levels caused a loss in Cdc42 activity and actin ring 
disruption. This was especially marked at the periphery of the actin ring where it co-
localized with LC3. Based on these findings, the possibility exists that LC3 can regulate 
bone-resorbing activity via Cdc42-dependent actin ring formation and ruffled border 
organization. 29 Overall these observations confirm an important, non-canonical role for 
autophagy in the regulation of osteoclast formation and function. 
Osteoclast Function and Autophagy: There is a considerable amount of new 
evidence that points to a role for the autophagic process in the clearance of cytotoxic 
protein aggregates – these accumulate in disease states due to impairment of the 
ubiquitin proteasome system (UPS) system. Aberrant, misfolded proteins, along with 
chaperones, are commonly found in p62 and ubiquitin-positive aggregates 
(sequestosomes) which are precursors to the inclusion bodies seen in many age-related 
neurodegenerative and liver diseases. 30  Several proteins that have been linked to 
autophagic regulation of protein aggregates include autophagy-linked FYVE protein 
(ALFY), SQSTM1/p62, NBR1, nuclear dot protein (NDP)52, optineurin (OPTN) and 
valosin containing protein (VCP).  Currently, it is not clear if their involvement is limited 
to selective autophagy or bulk autophagy in response to starvation. However, as noted 
previously some of these proteins act as autophagy cargo receptors (e.g. NBR1 and 
SQSTM1), whilst others are adaptors (e.g. ALFY) which facilitate autophagosome 
membrane formation around the cargo to be degraded.31In osteoclasts, ALFY interacts 
directly with SQSTM1 (via its PH-BEACH domain), ATG5 (via its WD40 repeat domain) 
and phosphatidylinositol-3-phosphate (PI3P) (via its FYVE domains) and forms large 
cytoplasmic aggregates (see section 4). 32  
Using an ALFY siRNA knock Filimonenco et al. 33 showed that while there was no 
direct effect on starvation-induced autophagic clearance of Htt poly Q protein, ALFY 
nuclear localization and shuttling may be the rate limiting step for aggregate clearance 
in HeLa and N2a cells. When compared to mononuclear precursors, amino acid 
starvation of mature multinucleated cells resulted in ALFY rapidly relocating to the 
cytoplasm and interacting and co-localizing with SQSTM1 in cytoplasmic aggregates. 
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Importantly, ALFY together with the proteins mentioned above can be linked to skeletal 
homeostasis; SQSTM1 and VCP mutations as well as OPTN genetic variants are linked 
to human disorders associated with a skeletal phenotype (see section 4) while NBR1 
regulates osteoblast function (see section 2). 10,34 The important role of autophagy in 
mature osteoclast function and survival is probably best illustrated by consideration of 
the osteoclast-specific effect of SQSTM1 mutations observed in patients with Paget’s 
disease of bone (PDB).  
 
4. Autophagy and the Pathogenesis of Paget’s Disease of Bone  
 
Pathogenesis of PDB: PDB is a common age-dependent skeletal disorder 
characterized by focal areas of increased and disorganized bone turnover. Clinically, if 
left unchecked, PDB can cause bone deformity and fracture. 35 PDB is principally a 
disorder of the osteoclast, characterized by an increase in their number, size and 
activity within the bone lesion. PDB osteoclasts exhibit increased sensitivity to RANKL 
in vitro and appear to be more resistant to apoptosis.36 The underlying cause(s) of the 
abnormal osteoclast activity and function in PDB is unclear, although evidence for a 
secondary involvement of osteoblasts in lesion development, is now emerging.35 
The etiology of PDB involves a complex interplay between genetic and environmental 
factors 37-39 with some studies implicating paramyxovirus infection.40 Interestingly, many 
viruses exert their effects by subverting autophagy, although to date no studied have 
directly determined the impact of viral infection on osteoclast autophagy. As many as 
40% of patients have a positive family history of disease and PDB is 7–10 times more 
common in first-degree relatives of affected individuals.41 Current thinking is that PDB is 
caused by a combination of rare, high-penetrance variants in small number of genes, 
together with common variants in other genes which together increase the risk of 
developing the disorder. 
The only gene to date identified as being causally related to PDB is SQSTM1, which 
encodes the autophagy receptor SQSTM1/p62 protein.42 However, SQSTM1 mutations 
are found only in 5-20% of PDB patients.43 The functional domains of SQSTM1 include 
a UBA domain, an N-terminal PB1 domain and two internal regions representing an LIR 
and KIR (KEAP1-interacting region). It co-localizes with LC3 in cellular ‘protein bodies’, 
including those containing aggregated mutant proteins, a process dependent on both 
the UBA and Phox and Bem1p (PB1) domains.30 The direct interaction (via the LIR) of 
SQSTM1 with LC3 facilitates the autophagic degradation of ubiquitin-modified cytosolic 
protein aggregates and organelles.44,45 However, the precise complement of autophagic 
substrates of SQSTM1 in vivo remains to be fully clarified.  
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Consistent with its role as a cargo receptor for the autophagic degradation of ubiquitin-
modified targets, SQSTM1 is up-regulated by various stressors including starvation, 
proteasome inhibition, and NF-κB and NRF2 activation. Functionally, it cooperates with 
the autophagy receptor NBR1via PB1 domain-mediated interactions, and as was noted 
earlier in osteoclast-like cells with ALFY to facilitate degradation of misfolded 
proteins.32,45 Further, interaction of SQSTM1 via its KIR region regulates the levels of 
this adapter protein. ,47, 48 KEAP1 in turn controls levels and activity of the NRF2 
transcription factor which regulates the expression of cytoprotective genes, thus 
contributing to the cell’s capacity to defend itself against chemical and oxidative stress 
and controls proliferation and differentiation of osteoblasts. 49 Interestingly, KEAP1 is 
also reported to down-regulate TNFα-induced NF-κB activation through autophagic 
degradation of IKKβ 50,51  Recent work shows a direct and functional interaction between 
SQSTM1 and components of mTORC1, establishing it as key regulator of nutrient 
sensing.52 In terms of regulation of SQSTM1-mediated autophagic function at the 
molecular level,, phosphorylation of the UBA domain at Ser403 was found to serve as a 
signal to promote autophagy.53 Ser403 phosphorylation appears to regulate the 
ubiquitin-binding ability of p62 and a phosphomimetic mutant (S403E) was shown to 
promote the formation of ‘sequestosomes’, presumed to be precursors of 
autophagosomes.53 Genetic inactivation of SQSTM1 in mice results in impaired 
osteoclastogenesis in vitro and in vivo.52  and importantly, in a mouse carrying a P394L-
p62 missense mutation (equivalent to the most common PDB-associated P392L human 
mutation), a PDB-like disorder was seen with altered osteoclast autophagy (see later).  
Disease Mechanisms: At the protein level, most of the disease-associated mutations 
affect the UBA domain of SQSTM1 and cause a loss of ubiquitin-binding activity.54-55 
While the PDB-mutant SQSTM1 causes an increase in osteoclast activity involving NF-
κB signaling, 56,57 little is known of the impact of the mutation on autophagy. As there is 
crosstalk between the two systems,58 changes in NF-κB activity and autophagic function 
could be expected. For example, induction of autophagy in macrophages in response to 
TLR4 is associated with TRAF6-mediated ubiquitination of BECLIN-1 59 and TRAF6 may 
be degraded by a form of autophagy that is dependent on NDP52 (although not 
associated with the canonical conversion of LC3-I to LC3-II). 60 Further, the IKK 
complex, which is an essential mediator of the RANK-NF-κB pathway, contributes to the 
induction of autophagy and is activated by multiple autophagy inducers, without 
affecting NF-κB nuclear translocation.61 Conversely, levels of IκB, the inhibitor of NF-
κB, appear to be regulated by autophagy.51 Further emphasizing common pathways, 
under resting conditions BECLIN-1 forms a complex with the TGFβ-activated kinase 1 
(TAK1)-binding proteins (TAB) 2 and 3; during autophagy, BECLIN-1 activate IKKβ and 
induces autophagy. 62,63 NF-κB activation can also limit autophagy activators (BNIP3, 
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JNK1, and ROS) and increase expression of autophagy inhibitors (A20 and BCL-2/XL) 
(see review by Salminen et al 64). 
PDB-Associated Mutations of SQSTM1 and Autophagy: Indirect evidence supports 
the notion that alterations in autophagy are linked to the pathogenesis of PDB: disease-
causing mutations increase osteoclast activity; autophagy positively regulates 
osteoclast activity28 and SQSTM1, which is commonly mutated in PDB, is an autophagy 
receptor.  Further, PDB-associated mutations map to regions of SQSTM1 which are 
relevant for its autophagy-dependent function: principally the UBA domain,42, 65,  but also 
the LIR (D335E)66 and the KIR (S349T) domains. 67  
Earlier observations that SQSTM1 is over-expressed in PDB patient samples, 
regardless of SQSTM1 mutation status, were the first indication that autophagy may be 
altered in the pagetic state (Table 1). 68 However, perhaps the best evidence of 
alterations in autophagic function comes from studies of the P394L-p62 mouse, which, 
as noted earlier, develops a PDB-like bone disorder with focal bone lesions. 60 
Osteoclast precursors from the mutant animals, exhibit increased expression of 
SQSTM1, ATG5 and LC3 along with increased LC3-II protein levels in the presence of 
Bafilomycin (BAF) suggesting a possible increase in autophagic flux (and consistent 
with the known relationship between autophagic and osteoclastic activity). 28 In a cell 
model of PDB with SQSTM1 mutations, a preliminary report describes alterations in 
autophagic flux. 68 
Other Related Disorders and Autophagy: Curiously, SQSTM1 mutations, including 
some UBA domain mutations which are associated with PDB, have also been reported 
in patients with amyotrophic lateral sclerosis and frontotemporal lobar degeneration.69,70 
Interestingly, several of the recently identified new genes for ALS represent autophagy 
receptors including OPTN (also linked to PDB), UBQLN2 and VCP.69 The latter is 
perhaps the most relevant, given that VCP mutations are a cause of the multi-system 
disorder inclusion body myopathy associated with PDB and frontotemporal dementia. 
Although its precise role in autophagy is unclear, in muscle cells the mutant VCP 
appears to be linked to alterations in autophagy.71 Indeed, its expression was 
associated with accumulation of non-degradative autophagosomes and a failure to 
degrade aggregated proteins.72 In knock-out animals with mutant VCP there was 
increased levels of LC3B-II in muscle cells, osteoclast precursors exhibited increased 
sensitivity to RANKL, and there were focal bone lesions. 73 Finally, OPTN, encodes the 
autophagy receptor, OPTN/optineurin which been implicated in PDB74 with preliminary 
studies suggesting that it negatively regulates osteoclast activity. 75 
 
 5. Autophagy in the Growth Cartilage 
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Function of the Growth Plate: The epiphyseal growth plate is a transient form of 
cartilage located at sites of long bone growth and composed of chondrocytes embedded 
in a matrix containing collagen II and proteoglycan. In comparison with articular 
cartilage (see below), chondrocytes in the growth plate have a very short half-life (days, 
not years) 76. During growth, a number of well-defined zones can be delineated; most 
obvious is a columnar cell zone that contains proliferating cells. As these cells mature, 
they become terminally differentiated hypertrophic chondrocytes. Mineralization of the 
mature cartilage begins in the deep hypertrophic zone in cell-derived particles, matrix 
vesicles. Enzymes in the matrix vesicle, remove local inhibitors of mineralization, 
enhance calcium transport and localization and promote mineral deposition.77 During 
the growth period, there is evidence of chondrocyte autophagy and indeed treatment of 
rats with the autophagy activator rapamycin impairs longitudinal growth.78 
Autophagy and Chondrocyte Function: Regulation of the cellular changes described 
above is complex and involves aninterplay between  agents generated by chondrocytes, 
(PTHrp and Indian Hedgehog), cytokines and systemic factors including hormones of 
the hypothalamus-pituitary axis. 79, 80 Once mineralization has begun, there are 
autophagic changes in hypertrophic chondrocytes: reorganization of LC3-II and 
BECLIN-1 proteins into punctate granules.  In addition, transmission electron 
microscopy studies indicate the presence of double membrane vacuoles. Not 
surprisingly, suppression of MTOR causes a marked increase in chondrocyte 
autophagy. 81 Following autophagy, chondrocytes are deleted from the plate by the 
initiation of programmed cell death. 80These terminal changes and the control of growth 
through Wnt signaling pathway would suggest that autophagy serves not just to regulate 
the final stages of the chondrocyte life cycle, but also the rate at which chondrocytes 
enter the maturation process.  
Metabolic Control of Chondrocyte Autophagy: Chondrocytes generate metabolic 
energy through anaerobic glycolysis, an environmental adaptation that permits them to 
survive in the restricted vascular supply of cartilage. HIF-1 is expressed at high levels in 
hypertrophic chondrocytes. Conditional inactivation of the HIF-1α gene caused a 
reduction in the number of maturing hypertrophic cells, an elevation in numbers of 
apoptotic cells and a disorganized layer of subchondral (metaphyseal) bone. 82 To 
further explore this activity and relate it to autophagy, a chondrocyte line was developed 
(N1511) that mimics many of the phenotypic changes expressed by epiphyseal 
chondrocytes.83 When serum-stressed, these cells robustly expressed punctate LC3 
protein and BECLIN-1.83 
Not surprisingly, at a low pO2, the cultured chondrocytes are refractory to an apoptotic 
challenge. It was noted that HIF-1 suppressed BECLIN-1, leading to enhanced cell 
death. The observation that BECLIN-1 suppression resulted in increased BH3 
interacting-domain death agonist (BID), cleavage and caspase-8 activation clearly links 
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apoptosis with autophagy. Thus, BECLIN-1 served to maintain chondrocyte survival 
activity, possibly by regulating the activities of pro-apoptotic genes.83 Another HIF target 
is AMPK , a protein that responds to the energy status of the cell, and activated in a 
HIF-1-dependent manner. As might be expected this protein is robustly expressed in the 
glycolytic growth plate.884 A number of studies have shown a connection between 
AMPK (AMP activated protein kinase) and MTOR. Once activated, AMPK 
phosphorylates tuberous sclerosis protein 2 (TSC2) which then suppresses MTOR and 
hence promotes autophagy. By down-regulating the phosphorylation of targets S6K1 
and 4E-BP1, MTOR integrates multiple signals including those from nutrients, as well as 
metabolic signals from glycolysis and ATP.85  
From a physiological viewpoint, in the growth plate, autophagy is controlled by two 
environmental sensors: AMP kinase and MTOR and probably HIF via the prolyl-4-
hydroxylase domain (PHD) oxygen sensors 84. The hypoxic plate would foster the 
expression of HIF-1 and the high glycolytic activity would elevate AMP levels and 
suppress MTOR. Once autophagy is activated, it would serve to maintain the lifespan of 
the hypertrophic cell, thus allowing the cells to reach their final maturation stage. 
Eventually, extended autophagic activity would lead to sensitization of terminally 
differentiated chondrocytes to local and intrinsic signals, resulting in apoptosis, deletion 
of cells from the growth plate and bone growth.86 
6. Autophagy and the Pathogenesis of Lysosomal Storage Disorders 
(LSDs): The Mucopolysaccharidoses (MPSs) 
Lysosomal Storage Disorders: LSD are recognized as a cohort of nearly 60 different 
inherited disorders, each with a genetic defect that renders the lysosomal system 
dysfunctional and unable to degrade specific molecules. As a consequence, many 
tissues and organ systems are affected, including bone and cartilage.87 The MPSs 
comprise a group of LSDs caused by deficiency in the enzymes catalyzing the 
degradation of glycosaminoglycans (GAGs), which are long, repeating chains of 
complex sugar molecules, normally degraded in the lysosome.88 Multiple Sulfatase 
Deficiency (MSD) is a very severe form of MPS due to mutations in the Sulfatase 
Modifying Factor 1 (SUMF1) gene. 89 The SUMF1 protein is responsible for an essential 
post-translational modification of the sulfatase enzymes, a class of hydrolases that 
remove sulfate groups from different molecules including GAGs. Many sulfatases are 
lysosomal, and thus one of the major consequences of the lack of sulfatase activity is 
the accumulation of multiple sulfated substrates in the lysosomes. 90 The Sumf1-/- 
mouse recapitulates most of the features of the human MSD disease and in particular 
displays a remarkable skeletal dysplasia, characterized by severe shortening of the 
axial and appendicular skeleton.91 Multiple measurements of autophagy in 
Sumf1−/−chondrocytes revealed severe lysosomal vacuolization and an increased 
number of autophagosomes compared to wild-type chondrocytes. Since cells treated 
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with an inhibitor of lysosomal acidification (BAF) accumulate autophagic vacuoles and 
present with low ATP content, it is likely that the decreased survival of the 
Sumf1−/−chondrocytes is directly linked to the defective digestion of the autophagic 
cargo. 92  
Pathogenesis of the MPS: While the pathogenic mechanisms are still unclear, 
defective autophagy is a generalized phenomenon occurring in many LSD; cells and 
tissues isolated from patients and mouse models of LSD display higher number of 
autophagosomes compared to controls, most likely the result of a defective lysosome-
autophagosome fusion (Table 1). As a consequence, autophagic substrates, such as 
polyubiquitinated proteins and dysfunctional mitochondria, are significantly elevated in 
LSD cell and tissue samples. 93,94 Providing a direct insight into the biochemical defect, 
Sumf1-/- mice exhibited a significant accumulation of cholesterol in lysosomal 
membranes. As a consequence, there is impaired distribution of the SNARE (soluble 
NSF attachment protein receptors) that are key components of the cellular membrane 
fusion machinery. 95 Interestingly, wild-type cells “loaded” with cholesterol in vitro mirror 
the fusion defects observed in LSD cells. Conversely, lowering cholesterol levels 
restores normal lysosomal function. From this perspective, the lysosome-
autophagosome fusion defect in LSD reflects the abnormal lysosomal membrane lipid 
composition. 95 
 
7. Autophagy and the Pathogenesis of Osteoarthritis (OA) 
 
Pathogenesis of Osteoarthritis: OA is among the most prevalent aging-related 
diseases and the most prevalent joint disease. 96 The two main risk factors for OA are 
aging and mechanical load. Excessive mechanical loading can occur in the acute 
setting of joint injury or chronically due to abnormal joint shape, malalignment or as a 
result of occupational and recreational activities. 97 The earliest changes in cartilage are 
enzymatic degradation of GAGs and cartilage proteins, and loss of chondrocytes in the 
superficial zone; this region is exposed to shear and compressive forces during 
movement. 98 With depletion of many of the original chondrocytes, there is emergence 
of clusters of densely packed cells, which are phenotypically distinct from the original 
cartilage cells. Cell activation in OA cartilage has been interpreted as an unsuccessful 
attempt at tissue repair and as the condition progresses, it leads to further cartilage 
defects.99 
Changes in autophagy protein expression and activation in aging and OA: 
Conceptually, autophagy in normal adult articular cartilage is an important mechanism 
for cellular homeostasis. Thus, cells in the superficial zone display a robust expression 
of autophagy proteins BECLIN-1, ATG5 and LC3. 100 When LC3 was tagged with GFP, 
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the highest GFP signal was observed in cells present in the superficial and middle 
zones of the knee articular cartilage (Table 1). Few cells in the deep cartilage zone 
exhibited detectable levels of GFP-LC3 signal. As with other tissues, starvation 
increased the number of autophagosomes in chondrocytes.14 
During the aging process in mouse and human knee articular cartilage, there is a 
decrease in ULK1, LC3, and BECLIN-1 protein expression. The reduction of these key 
regulators of autophagy is accompanied by increased apoptosis.14 Using a rapidly 
progressing experimental mouse of OA, a time-dependent reduction in these autophagy 
proteins was noted.100 Since this reduction was observed in relatively young mice it is 
apparently not a consequence of aging-related events. However, for both surgical OA 
and mechanically injured cartilage, the increase in cell death suggests that autophagy 
may contribute to survival mechanisms. 
In contrast to the reduction in autophagic proteins in non-proliferating chondrocytes, the 
cell clusters in OA cartilage express high levels of these proteins100 thereby confirming 
an earlier study that suggested that chondrocytes in OA cartilage displayed numerous 
autophagic LC3 puncta.101 Levels of LC3-II were also increased in the superficial and 
middle zones in a rat model of OA.14 When full thickness cartilage explants were 
subjected to high impact mechanical compression, there were immediate matrix 
changes and a low level of cell death, accompanied by a short and transient increase in 
the levels of LC3-II, and a marked reduction in ULK1, LC3, and BECLIN-1.100 Thus, 
during the development of OA, increased autophagy may reflect an adaptive stress 
response. Further, failure to mount an autophagic response may lead to further 
degeneration. 
Consequences of dysregulated autophagy in OA: The reduction in autophagy 
protein levels and activity lends strong support to the hypothesis that basal autophagic 
activity decreases with age, thus contributing to the accumulation of damaged 
organelles and macromolecules and susceptibility to aging-related diseases.102 Indeed, 
prior studies demonstrated mitochondrial dysfunction in various animal models and in 
human OA.103 In addition, mitochondrial DNA mutations are known to increase in OA 
chondrocytes.104 Damaged mitochondria, producing high levels of ROS, promote pro-
inflammatory signaling, as they initiate formation of inflammasomes and activation of 
other inflammatory pathways.105 In knee chondrocytes, IL-1- or NO - dependent 
increase in expression of LC3 and BECLIN-1 activates autophagy.106 Further, 
autophagy activation prevents IL-1-mediated suppression of cartilage matrix 
degradation while reducing the levels of MMP-13, ADAMTS, (a disintegrin and 
metalloproteinase with a thrombospondin type 1 motif) 5 and ROS. Given that one of 
the cytoprotective functions of autophagy is removal of damaged mitochondria107, the 
IL-1–induced OA-like gene expression changes might possibly occur through reduction 
in the intracellular ROS level via elimination of damaged mitochondria. 
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As discussed earlier, HIF proteins have recently been linked to the regulation of 
autophagy in chondrocytes. 88 With respect to HIF-1, in the superficial cartilage zone, 
there is moderate level of protein expression; both expression and autophagy is 
increased in OA cells. 101 It is likely that HIF-1 upregulation due to the hypoxic state of 
the tissue serves to promote chondrocyte autophagy.  With respect to HIF-2α, in young 
animals, the highest expression level is in the superficial zone. In this case, upregulation 
of HIF-2α lowers intracellular ROS levels by promoting the activities of the dismutating 
proteins, catalase and superoxide dismutase; from this perspective, it can be regarded 
as cytoprotective. In OA cartilage, HIF-2α expression is induced in the earlier stage of 
OA, and it is down-regulated at later stages.108,109  
A second aspect of HIF-2α is that it increases expression of RUNX2 (runt-related 
transcription factor 2), a transcription factor, which induces expression of proteins 
associated with chondrocyte hypertrophy (collagen X, MMP13 and vascular endothelial 
growth factor A, (VEGFA).110 As RUNX2 and its target genes are overexpressed in OA 
cartilage, it has been suggested that chondrocytes express a differentiation program 
that is more characteristic of a hypertrophic state111. On this basis, increased HIF-2α-
induced RUNX2 activation and hypertrophic differentiation may promote OA. HIF-
2α over-expression promotes cartilage destruction and conversely, the severity of 
experimental OA is reduced in HIF-2α mutant mice.109, 112 Indeed, when HIF-2 is 
silenced, IL-1β-induced expression of ADAMTS4, MMP1, MMP3, MMP9, MMP12 and 
MMP13 is significantly decreased. Thus, the two HIF isoforms have overlapping but 
differing roles: while HIF-2α appears to be cytoprotective, HIF-1 both promotes 
autophagy while sensitizing cells to local apoptogens, Put another way, HIF-2α 
regulates the extent of the autophagic response and can be viewed as acting as a brake 
to the accelerator function of HIF. Finally it should be noted that stress or cytokine 
induced activation of HIF-2α, could outweigh the homeostatic effects of HIF-1α, and 
promote chondrocyte hypertrophy, cell death and matrix degradation.101 The marked 
inhibition of autophagy would negatively impact chondrocyte survival and differentiation.  
8. Therapeutic targets for skeletal disease 
This review highlighted the import of the autophagic response in relationship to the 
pathogenesis of diseases affecting bone and cartilage. The authors suspect that aside 
from disorders discussed here in some detail, there are hints that autophagic 
dysfunction may influence other diseases of the skeletal tissues. An incomplete list 
would include growth disorders, disregulated endocrine function, osteoporosis, fibrous 
dysplasia, rheumatoid arthritis and degenerative disc disease.  
A priori, before delineating therapies directed at removing dysfunctional organelles and 
accumulated aggregated proteins, the underlying autophagic ‘defects’ needs to be 
defined with care. From what is already known of the autophagic process, it is clear that 
unless the nature of the defect is established, promotion of autophagic flux may well 
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trigger the induction of apoptosis or even senescence.  In this case, for many skeletal 
tissues where cell numbers are normally low and longevity is extended, this type of 
treatment would exacerbate the disease state. In contrast, when the site of aberrant 
dysfunction is known, modulation of the autophagy response may be a rational 
approach for treatment of conditions like the MPS.  
While caution is urged, there have been some attempts to modify skeletal cell function 
through modulators of the autophagic response. Of the drugs examined, in OA tissues, 
the autophagy activator rapamycin has been shown to prevent cell death and GAG loss, 
maintain cartilage cellularity and decrease the expression of ADAMTS-5, an important 
enzyme in cartilage extracellular matrix degradation. 113 Likewise, on the basis of 
PMTOR and or p-p70S6K expression, there is evidence indicating that over 50% of 
chordomas, tumors of the intervertebral disc are responsive to MTOR inhibitors. 
114Since this kinase is the nexus for signals from the AKT/PI3K, MAPK/ERK1/2 and P53 
signaling pathway, as well as nutrient (amino acid) levels and sensors of the oxygen 
and energy status, there is likely to be multiple sites for control of these skeletal tumors. 
Undoubtedly, molecular delineation of the autophagic process in skeletal tissues will 
provide unique functional insights, while at the same time uncover new approaches to 
treating the host of diseases that affect the axial and appendicular skeleton. 
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FIGURE 1. (LEGEND) 
Autophagy in bone, articular cartilage, the growth plate and articular cartilage. A. 
Schematic showing cellular control of bone remodeling. A basic multicellular unit 
consists of osteoblasts (OB) osteoclasts (OC) and bone lining cells (LC). Pro-
osteoclasts (PrOC) and pro-osteoblasts (prOB) enter the unit through capillaries (CAP) 
and home to the bone surface where they undergo differentiation into OB and OC 
respectively. A number of osteoblasts will undergo terminal differentiation and become 
osteocytes (O’CYTES). Under the influence of local factors including those secreted by 
osteoblasts (MCF, RANKL), pro-osteoclasts differentiate and resorb bone liberating 
Ca2+ and amino acids (AA) from the bone matrix. Sclerostin an inhibitor of osteoblast 
activity is also released from the bone matrix. At these sites, a resorption lacuna can be 
seen (RL). Another secreted factor, osteoprotegrin (OPG), inhibits osteoclast mediated 
bone resorption by serving as a physiological inhibitor of RANKL. A number of factors 
are released from the resorbing bone that include BMP and TGFβ. These proteins 
promote osteoblast maturation and osteoid synthesis and mineralization.  B Schematic 
of a long bone showing articular cartilage (AC), growth plates (GP) and bone marrow 
(BM). C. Section through a demineralized osteon showing the presence of autophagic 
osteocytes (inset, stained with an anti LC3 antibody). From Zahm et al., Cells Tissues 
Organs. 2011;194(2-4):274-8D, and with permission from  S. Karger AG.  D. Section 
through the rat growth plate showing the presence of autophagic pre-hypertrophic 
chondrocytes (arrows) stained with an antibody to LC3. From Srinivas et al.,  Cells 
Tissues Organs. 2009;189(1-4):88-92 and with kind permission from  S. Karger AG. E. 
Chondrocyte autophagy in knee cartilage of GFP-LC3 transgenic mice. Confocal 
microscopy rendered reconstruction using 3D IMARIS (Bitplane Inc.) indicating that the 
highest levels of GFP-LC3 signal were observed in chondrocytes in the superficial and 
upper middle zone of the articular cartilage. In contrast, only few cells in the deep zone 
contained detectable levels of GFP-LC3 signal. Mag x 63. 
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